Patent DE1213571B successfully refreshed from Google Patents.
US5779661A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating dysfunctional bladder syndromes by electromotive drug administration
Assignee: Physion Srl
•
Filing: 1995-12-11
•
Granted: 1998-07-14
•
Expires: 2015-12-11
Abstract
Abstract An intravesical method of treating dysfunctional bladder syndromes by Electromotive Drug Administration (EMDA) of local anaesthetic drugs, anti muscarinic drugs and sympathomimetic agents. The administration of said drugs combined with hydraulic bladder dilatation causes relaxation of the detrusor muscle, reversing the hypertonicity associated with dysfunctional bladder syndromes.
Inventors
- 👤 Robert L. Stephen
- 👤 Manfred Stohrer
- 👤 Umberto Fontanella
- 👤 Donald P. Griffith
- 👤 Franco Lugnani
- 👤 Cino Rossi
- 👤 Silvio Eruzzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:25
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/18; A61N1/20; A61N1/30; A61N1/303; A61N1/306; A61N1/32; A61N1/325
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
169 words
A method of treating dysfunctional bladder syndromes by Electromotive Drug Administration of intravesically instilled drug into a bladder wall, said method comprising the steps of: a) inserting a catheter via a urethra into a bladder and draining said bladder of urinary contents, b) administering into said bladder via said catheter an electrically conductive aqueous solution comprising at least a local anaesthetic agent and an antimuscarinic agent to achieve both analgesia and relaxation of the detrusor muscle, c) inserting into said catheter a tubular anodic electrode connected to an external controllable power source, so that the internal tip of said electrode resides within that section of said catheter which is within the bladder cavity, d) placing in contact with an adapted skin location a cathodic electrode also connected to said external power source, e) supplying an electrical current from said power source to said electrodes, f) instituting a progressive active hydraulic dilatation of said bladder by infusing, portionwise, through said catheter, a solution to substantially achieve its maximum intravesical volume.
Claim 2
Independent Claim
169 words
A method of treating dysfunctional bladder syndromes by Electromotive Drug Administration of intravesically instilled drug into a bladder wall, said method comprising the steps of: a) inserting a catheter via a urethra into a bladder and draining said bladder of urinary contents, b) administering into said bladder via said catheter an electrically conductive aqueous solution comprising at least a local anaesthetic agent and an antimuscarinic agent to achieve both analgesia and relaxation of the detrusor muscle, c) inserting into said catheter a tubular anodic electrode connected to an external controllable power source, so that the internal tip of said electrode resides within that section of said catheter which is within the bladder cavity, d) placing in contact with an adapted skin location a cathodic electrode also connected to said external power source, e) supplying an electrical current from said power source to said electrodes, f) instituting a progressive active hydraulic dilatation of said bladder by infusing, portionwise, through said catheter, a solution to substantially achieve its maximum intravesical volume.
Claim 3
Dependent Claim
32 words
A method according to claim 1, wherein the solution of step f) is an electrically conductive aqueous solution including a local anaesthetic agent at a concentration of 0.3 to 2% by weight/volume.
Claim 4
Dependent Claim
24 words
A method according to claim 1, wherein said local anaesthetic agent is selected from the group consisting of lidocaine, mepivacaine, bupivacaine, and mixtures thereof.
Claim 5
Dependent Claim
29 words
A method according to claim 3, wherein said local anaesthetic agent is administered in the form of an aqueous solution at a concentration of 0.3% to 2.0% by weight/volume.
Claim 6
Dependent Claim
17 words
A method according to claim 1, wherein said electrically conductive aqueous solution further comprises a sympathomimetic agent.
Claim 7
Dependent Claim
22 words
A method according to claim 5, wherein said sympathomimethic agent is selected from the group consisting of epinephrine, ephedrine and mixture thereof.
Claim 8
Dependent Claim
39 words
A method according to claim 1, wherein a volume of from 50 to 150 ml of said electrically conductive aqueous solution is administered and an electrical current having an intensity of from 10 mA to 30 mA is supplied.
Claim 9
Independent Claim
168 words
A method of treating dysfunctional bladder syndromes by Electromotive Drug Administration of intravesically instilled drug into a bladder wall, said method comprising the steps of: a) inserting a catheter via a urethra into a bladder and draining said bladder of urinary contents, b) administering into said bladder via said catheter an electrically conductive aqueous solution of at least one drug which causes relaxation of the detrusor muscle, c) inserting into said catheter a tubular anodic electrode connected to an external controllable power source, so that the internal tip of said electrode resides within that section of said catheter which is within the bladder cavity, d) placing in contact with an adapted skin location a cathodic electrode also connected to said external power source, e) supplying an electrical current from said power source to said electrodes, f) instituting a passive hydraulic dilatation of said bladder by clamping said catheter and thereby trapping inflowing urine within the bladder cavity and distending said bladder to substantially achieve its maximum intravesical volume.
Claim 10
Independent Claim
168 words
A method of treating dysfunctional bladder syndromes by Electromotive Drug Administration of intravesically instilled drug into a bladder wall, said method comprising the steps of: a) inserting a catheter via a urethra into a bladder and draining said bladder of urinary contents, b) administering into said bladder via said catheter an electrically conductive aqueous solution of at least one drug which causes relaxation of the detrusor muscle, c) inserting into said catheter a tubular anodic electrode connected to an external controllable power source, so that the internal tip of said electrode resides within that section of said catheter which is within the bladder cavity, d) placing in contact with an adapted skin location a cathodic electrode also connected to said external power source, e) supplying an electrical current from said power source to said electrodes, f) instituting a passive hydraulic dilatation of said bladder by clamping said catheter and thereby trapping inflowing urine within the bladder cavity and distending said bladder to substantially achieve its maximum intravesical volume.
Claim 11
Dependent Claim
23 words
A method according to claim 8, wherein the at least one drug which causes relaxation of the detrusor muscle comprises an antimuscarinic agent.
Claim 12
Dependent Claim
47 words
A method according to claim 9, wherein said antimuscarinic agent is selected from the group consisting of atropine, scopolamine, homatropine, dicyclomine, oxyphencyclamine, flavoxate, oxybutynin, methantheline, methscopolamine, octatrophine, parapenzolate, pentapiperide, pipenzolate, prifinium, propanteline, butylscopolamine, tiemonium, xenytropium, dihexyverine, propiverine, terodyline, diphemanile, emepronium, hexacyclium, fentonium, isopropamide, trospium, and mixtures thereof.
Claim 13
Dependent Claim
28 words
A method according to claim 9, wherein said antimuscarinic agent is administered in the form of an aqueous solution at a concentration of 0.001% to 0.2% by weight/volume.
Claim 14
Dependent Claim
31 words
A method according to claim 9, wherein said antimuscarinic agent is administered in the form of a sodium or potassium citrate solution at a concentration of 1.0% to 3.0% by weight.
Claim 15
Dependent Claim
38 words
A method according to claim 8, wherein the at least one drug which causes relaxation of the detrusor muscle is administered in the form of a physiological electrolyte solution having an osmolarity of from 150 to 310 milliosmols.
Claim 16
Dependent Claim
29 words
A method according to claim 8, wherein the at least one said drug which causes relaxation of the detrusor muscle comprises a local anaesthetic agent and an antimuscarinic agent.
Claim 17
Dependent Claim
39 words
A method according to claim 8, wherein a volume of from 50 to 150 ml of said electrically conductive aqueous solution is administered and an electrical current having an intensity of from 10 mA to 30 mA is supplied.
References Cited (Backward Citations)
US4411648A
Cited
US4744787A
Cited
US4747819A
Cited
US4752285A
Cited
US4752285B1
Cited
US4878892A
Cited
DE3809814C1
Cited
US5002956A
Cited
US5167616A
Cited
US5236413A
Cited
US5236413B1
Cited
US5147294A
Cited
US5234408A
Cited
US5328451A
Cited
US5222936A
Cited
US5232441A
Cited
US5301688A
Cited
US5401239A
Cited
US5486160A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-13 | 2002-01-12 | 2002-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-13 | 2006-01-12 | 2006-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-13 | 2010-01-12 | 2010-07-14 | $7700.00 | Window Closed / Lapsed |